DCF — ST ELIZABETH BOARDMAN HEALTH CTR
Enterprise Value: $251.5M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$251.5M
Enterprise Value
$67.3M
PV of Cash Flows
$184.2M
PV of Terminal Value
$296.6M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $275.3M | $31.4M | 11.0% | $13.6M | $12.4M |
| Year 2 | $283.6M | $35.2M | 12.0% | $16.1M | $13.3M |
| Year 3 | $292.1M | $39.1M | 13.0% | $18.8M | $14.1M |
| Year 4 | $300.8M | $41.8M | 14.0% | $20.5M | $14.0M |
| Year 5 | $309.8M | $43.8M | 14.0% | $21.7M | $13.5M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $251.5M. Terminal value accounts for 73% of total EV — typical range (60-80%).
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$267.3M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base0.10900622763337958
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5